Relief of migraine accompanied by aura and without aura.
Hypersensitivity to Zolmitriptan. Severe or moderate hypertension and uncontrolled mild increase in blood pressure, coronary heart disease, including myocardial infarction. Vasospastic angina (Prinzmetal angina). Cerebrovascular disorders, and transient ischemic attack in history. Creatinine clearance <15 mL / min. Simultaneous administration of ergotamine, derivatives of ergotamine, sumatriptan, naratriptan or other agonists of 5HT1B / 1D receptors. Peripheral vascular disease. Advanced age (> 65 years).
Dosage & Administration
product is not intended for use in the prophylaxis of migraine attack. Rapimig recommended as soon as possible after the onset of a migraine attack, although its effectiveness is not dependent on how long the tablet was taken after symptom onset.
The tablet can not drink the liquid. The tablet is placed on the tongue, where it dissolves and is swallowed with the saliva. This dosage form can be used in situations where there is no fluid under hand or to avoid nausea and vomiting which may occur when the liquid zapivaniya tablets.
This dosage form dissolves quickly in the mouth, but sometimes still can delay the absorption of zolmitriptan and delaying the onset of drug action.
The blister pack should be disclosed by cleaning it from the foil, and not by forcing foil tablet.
The recommended dose for Rapimiga eliminate migraine attacks – one tablet (2.5 mg). If symptoms persist or recur within 24 hours can be an effective use of the second dose. If the application of the second dose is necessary, it should take no sooner than 2 hours after the first. In inefficiency permitted dose of 2.5 mg single dose increasing to 5 mg (maximum single dose).